PT141 10mg

PT141 is a research peptide studied for its potential effects on sexual function and arousal in both men and women. This 10mg vial is designed for laboratory and research purposes only. PT141 works through a different mechanism than traditional treatments, targeting melanocortin receptors in the brain rather than vascular pathways. Research suggests it may promote spontaneous desire and improve response regardless of psychological state. Each vial contains 10mg of lyophilized peptide powder. Intended for qualified researchers and educational use in controlled settings.

Peptide Sequence: PT-141 (Bremelanotide analog) Molecular Weight: 1025.18 g/mol Purity: ≥98% (HPLC) Form: Lyophilized powder Vial Size: 10mg Storage: Keep refrigerated at 2–8°C. Protect from light. Reconstitution: Reconstitute with sterile water or bacteriostatic saline as needed for research applications. Research Use Only: Not for human consumption. For laboratory and qualified research purposes only.

Molecular Formula: C50H71N15O10 CAS Number: 189691-06-3 Amino Acid Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2

Storage Before Reconstitution: Store lyophilized powder at 2–8°C in a refrigerator. Keep vial tightly sealed in its original container. Protect from light and moisture. Under these conditions, the peptide remains stable for up to 24 months. Storage After Reconstitution: Once reconstituted with sterile water or bacteriostatic saline, store the solution at 2–8°C. Reconstituted PT141 is stable for approximately 2–4 weeks when kept refrigerated and protected from light. For extended storage, freeze reconstituted solution at −20°C, where it remains viable for several months. Avoid repeated freeze-thaw cycles.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. PT-141 (Bremelanotide) Origins: Derivation from Melanotan II
   Hadley ME & Dorr RT. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921–930. https://doi.org/10.1016/j.peptides.2005.01.029
   Reviews the development of melanocortin peptide analogues including the derivation of PT-141 (bremelanotide) from Melanotan II, detailing the structure–activity relationships that led to its cyclic heptapeptide design and selective melanocortin receptor profile.
2. Melanocortin Receptor Pharmacology: MC3R and MC4R
   Wikberg JE, et al. (2000). New aspects on the melanocortins and their receptors. Pharmacological Research, 42(5), 393–420. https://doi.org/10.1006/phrs.2000.0725
   Comprehensive review of the five melanocortin receptor subtypes (MC1R–MC5R), their tissue distribution, and signalling pathways — establishing the receptor pharmacology through which PT-141 exerts its central nervous system effects via MC3R and MC4R activation.
3. PT-141 and Central Mechanisms of Sexual Arousal
   Molinoff PB, et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 994, 96–102. https://doi.org/10.1111/j.1749-6632.2003.tb03167.x
   Characterises PT-141’s mechanism of action as a centrally acting melanocortin agonist, demonstrating that its pro-erectile and pro-arousal effects in preclinical models are mediated through hypothalamic MC4R activation rather than peripheral vascular pathways — distinguishing it mechanistically from PDE5 inhibitors.
4. PT-141 Phase 2 Clinical Research in Male Subjects
   Diamond LE, et al. (2004). A double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research, 16(1), 51–59. https://doi.org/10.1038/sj.ijir.3901139
   Double-blind, placebo-controlled Phase 2 trial evaluating intranasal PT-141 pharmacokinetics and pharmacodynamics, demonstrating significant pro-erectile activity and establishing the compound’s safety and tolerability profile in a controlled clinical research setting.
5. Bremelanotide (PT-141) in Female Sexual Dysfunction Research
   Clayton AH, et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health, 12(3), 325–337. https://doi.org/10.2217/whe-2016-0018
   Randomised, placebo-controlled dose-finding trial of bremelanotide (PT-141) in premenopausal women, providing key pharmacodynamic and tolerability data across dose ranges and establishing the research basis for melanocortin agonism in female sexual arousal disorder models.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.